Last reviewed · How we verify
Zyvox 600mg, BID
At a glance
| Generic name | Zyvox 600mg, BID |
|---|---|
| Also known as | Zyvox Tablet |
| Sponsor | LigaChem Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Linezolid Plus Standard of Care (NA)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Linezolid for Syphilis Pilot Study (PHASE2)
- Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection (PHASE1)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zyvox 600mg, BID CI brief — competitive landscape report
- Zyvox 600mg, BID updates RSS · CI watch RSS
- LigaChem Biosciences, Inc. portfolio CI